MedTrace Logo

Safety &Efficacy of CF101 to Subjects With Uveitis

NCT01905124 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-02-01

No results posted yet for this study

Summary

This is a Phase 2, randomized, double-masked, placebo-controlled study subjects with active, sight-threatening, noninfectious intermediate or posterior uveitis.

Conditions

  • Uveitis, Posterior
  • Uveitis, Intermediate

Interventions

DRUG

CF101

CF101 1 mg tablets orally every 12 hours for 24 weeks

DRUG

Placebo

Matching placebo tablets orally every 12 hours for 24 weeks

Sponsors & Collaborators

  • Can-Fite BioPharma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-31
Primary Completion
2019-09-30
Completion
2019-10-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01905124 on ClinicalTrials.gov